Evidence map›Paper›PMID 32521498›Full record

ArticleStem cell research2020

Rates of homology directed repair of CRISPR-Cas9 induced double strand breaks are lower in naïve compared to primed human pluripotent stem cells.

Benjamin T Dodsworth, Klas Hatje, Claas Aiko Meyer, Rowan Flynn, Sally A Cowley

Open access · goldAbstract read
In one paragraph

Article in Stem cell research, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.2field-weighted citation impact, top 50% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 5 citations in OpenAlex.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 3 institutions in 2 countries.

Benjamin T DodsworthSir William Dunn School of Pathology, University of Oxford, South Parks Road, OX1 3RE, United Kingdom; Roche Pharma Research and Early Development, Roche Innovation Center Basel, Basel, Switzerland.
Klas HatjeRoche Pharma Research and Early Development, Roche Innovation Center Basel, Basel, Switzerland.
Claas Aiko MeyerRoche Pharma Research and Early Development, Roche Innovation Center Basel, Basel, Switzerland.
Rowan FlynnCenso Biotechnologies, Roslin Innovation Centre Charnock Bradley Building, Easter Bush Campus EH25 9RG, United Kingdom.
Sally A CowleySir William Dunn School of Pathology, University of Oxford, South Parks Road, OX1 3RE, United Kingdom. Electronic address: sally.cowley@path.ox.ac.uk.
Roche (Switzerland) · CHRoslin Cells (United Kingdom) · GBUniversity of Oxford · GB

Funding

Medical Research Council MC_EX_MR/N50192X/1Medical Research Council MR/L023784/1Medical Research Council MR/M024962/1
6 · The paper itself

Abstract

Gene editing in human pluripotent stem cells (hPSC) is a powerful tool for understanding biology, for drug discovery and gene therapy. Naïve hPSC have been suggested to be superior for gene editing compared to conventional 'primed' hPSC. Using droplet digital PCR, we uncover the kinetics of Cas9-induced double strand break repair in conventional hPSC. Cut but unrepaired alleles reach their maximum after 12-24 h. Homology directed repair plateaus after 24 h, whereas repair by non-homologous end joining continues until 48 h after Cas9 introduction. Using this method, we demonstrate that the rate of homology directed repair to resolve Cas9-induced double strand breaks is 40% lower in naïve hPSC compared to conventional hPSC, correlating with, and feasibly explained by, a higher number of cells in G

Indexed as

CRISPR-Cas SystemsPluripotent Stem CellsDNA Breaks, Double-StrandedDNA End-Joining RepairGene EditingHumansRecombinational DNA RepairGene editing efficiencyGround stateHDRHomologous recombinationHomology directed repairHRHumanNaïveNHEJNon-homologous end joiningPluripotencyPluripotentStem cell

Identifiers

PMID32521498
PMCPMC7347009
OpenAlexW3033505600

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.